Replies to post #5070 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Thanks Al100.

The potential $200 million in revenue is based on 10,000 prescriptions and does not factor in the large potential growth from the targeted patient population of 4 million in the US alone. It does not consider the growth potential that can be generated by the results of the 50 open clinical trials presently underway, of which 23 are phase 3 or phase 4 trials.

Clinial Trials